Progyny Inc. priced its IPO of 10 million common shares at $13 per share.

The company is offering 6.7 million common shares, while selling stockholders of the company are offering the remaining 3.3 million shares.

Certain selling stockholders also granted underwriters a 30-day option to buy up to an additional 1.5 million common shares at the same price.

Progyny's shares are expected to begin trading on the Nasdaq Global Select Market under the PGNY symbol on Oct. 25. The IPO is expected to close Oct. 29.

J.P. Morgan, Goldman Sachs & Co. LLC and BofA Securities are acting as joint lead book-running managers for the IPO, while Citigroup is acting as book-running manager. Piper Jaffray, SVB Leerink and TPG Capital BD LLC are acting as co-managers for the offering.

The New York-based company, which provides fertility services, previously said it plans to use the proceeds for general corporate purposes, working capital, operating expenses and capital expenditures.

Additionally, funds raised may be used for the acquisition of complementary businesses, services or technologies.